Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms By Ogkologos - August 6, 2025 607 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR 2023 Highlights in Treating Genitourinary Cancers: Expert Perspectives January 24, 2024 Drug Combo JAKs Up Immunotherapy in Two Clinical Trials August 8, 2024 Neratinib Plus Capecitabine Outperforms Lapatinib Plus Capecitabine in Asian Patients with... November 21, 2020 FDA Approves Second CAR T-Cell Therapy for Lymphoma May 22, 2018 Load more HOT NEWS Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With... Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function... Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death... GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients...
